X
Pharma Advancement
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    development of new antibiotics

    EMA guidance supports development of new antibiotics

    Thermo Fisher Scientific Announces Collaboration with Northeastern University to Advance Biopharmaceutical Characterization and Monitoring Workflows

    Commercial Success In New Biopharmaceutical Innovation Era

    Proteros and AstraZeneca Boost Collaboration Agreement

    Conver to wp

    AbbVie and Cugene Join Forces Concerning Autoimmune Disorders and Cancer

    Drug Imagent For Therapeutic Platform

    Japan Pharma Lobby Says-Price Scheme Is Causing Drug Lag

    Charles River and Valence Discovery Announce Strategic Partnership to Provide Clients with AI-Enabled Drug Design Capabilities

    Charles River and Valo Launch Logica, an Integrated AI-Powered Drug Discovery Solution to Rapidly Deliver Optimized Preclinical Assets

    AstraZeneca announces phase IV ASCENT trial of Tudorza Pressair in patients with COPD meets primary efficacy endpoint

    AstraZeneca announces plans for new strategic R&D centre and Alexion headquarters in Cambridge, Massachusetts

    Lynparza approved in the EU for BRCA-mutated metastatic pancreatic cancer

    Major Success Factors For Clinical Development Organizations

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

    ArisGlobal Expands LifeSphere Clinical Portfolio with Landmark Customer Wins in APAC & Middle East

  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Market Moves

U.S. In Vitro Diagnostics (IVD) Market by Technology , Application , End User & by Region – Forecast to 2020

Yuvraj_pawp by Yuvraj_pawp
18th March 2016
in Market Moves

Report DescriptionTable of ContentSummaryRequest Sample

The U.S. IVD market is projected to reach USD 25.99 Billion by 2020 at a CAGR of 4.7% during the forecast period of 2015 to 2020. Some of the key factors driving the growth of this market are the rising incidence of chronic and infectious diseases in the U.S., rapidly aging population, growing preference for point-of-care testing and personalized medicine, implementation of the Affordable Care Act (ACA), increasing adoption of automated instruments, and automation in laboratories. The extending reach of molecular diagnostics and new range of condition-specific markers and tests with advances in genomics and proteomics are creating new opportunities for this market. However, the unfavorable reimbursement and lack of sufficient budget is hampering the growth of the U.S. IVD industry. Stringent regulatory framework presents a significant challenge to the market growth.

Over the past few years, the U.S. in vitro diagnostics market has witnessed steady growth owing to the increasing demand for high-performance products. Increasing urbanization and changing lifestyles have resulted in the growing incidence of chronic ailments such as diabetes, blood pressure, and cardiovascular diseases. This is further fueling the demand of innovative in-vitro diagnostic products for the early detection and diagnosis of these diseases. As a result, currently, most of the leading players in the in vitro diagnostics market are focusing on acquisitions as a major strategy to capture market share and sustain their leadership position in this market. Acquisition of similar or smaller players has enabled these companies to achieve greater competitiveness through the expansion of their product portfolio and technological expertise in a short period of time.

Geographically, the U.S. is the largest regional segment of the global IVD market. The large share of this region can be attributed to the accessibility to technologies, superlative opportunities for molecular diagnostics in genetic testing and cancer screening, established distribution channels, and the presence of a large number of market players such as Abbott Laboratories, Inc., Johnson & Johnson, Becton, Dickson and Company, Danaher Corporation, Thermo Fisher Scientific, Inc., Bio-Rad Laboratories, Inc., and Alere, Inc. Roche Diagnostics Limited (Switzerland), Danaher Corporation (U.S.), Siemens Healthcare (Germany), Thermo Fisher Scientific Inc. (U.S.), and Abbott Laboratories, Inc. (U.S.) are the leading companies, which accounted for ~50-55% of the market in 2014. However, new local players are intensifying competition and thereby threatening the market share of existing players. In order to maintain their shares, leading players are continuously adopting various strategies. This increased competitiveness is expected to drive innovation in the market, thereby driving market growth.

To know about the assumptions considered for the study, download the pdf brochure

Stakeholders of the Report:

  • IVD Product Manufacturers
  • Group Purchase Organizations (GPOs)
  • OEM Manufacturers
  • Clinical Laboratories
  • Distributors of IVD Products
  • Hospitals and Clinics
  • Healthcare Institutions
  • Research Institutes
  • Market Research and Consulting Firms
  • Venture Capitalists and Investors
  • Scope of the Report


This research report categorizes the U.S. IVD market on the basis of products & services, technologies, applications, and end users. These markets are further segmented, providing value analysis for 2013, 2014, and 2015, as well as forecast up to 2020. The end user market is comprehensively analyzed by region (South, Midwest, West, and Northeast) to provide in-depth information on the U.S. scenario.

U.S. In Vitro Diagnostics Market

This research report categorizes the U.S. in-vitro diagnostics market into the following segments:

U.S. In Vitro Diagnostics Market, by Products & Services

  • Reagents
  • Instrument
  • Fully Automated Instruments
  • Semi-automated Instruments
  • Others


Data Management Systems/Software

Services
U.S. In Vitro Diagnostics Market, by Technology

  • Clinical Chemistry
  • Immunochemistry/Immunoassay
  • Hematology
  • Coagulation & Hemostasis
  • Microbiology
  • Molecular Diagnostics (MDx)
  • Other Instruments


U.S. In Vitro Diagnostics Market, by Application

  • Infectious Diseases
  • Diabetes
  • Oncology/Cancer
  • Cardiology
  • Endocrine Disorders
  • Autoimmune Diseases
  • Bone & Mineral Disorders
  • Pulmonary Disorders
  • Others


U.S. In Vitro Diagnostics Market, by End User

  • Hospital Laboratories
  • Clinical/Independent Laboratories
  • Large Laboratories
  • Medium-sized Laboratories
  • Small Laboratories
  • Others


U.S. In Vitro Diagnostics End User Market, by Region

  • Hospital Laboratories Market
  • South
  • Midwest
  • West
  • Northeast


Clinical/Independent Laboratories

  • South
  • Midwest
  • West
  • Northeast
  • Others

Previous Post

Acrylic Acid Market by Derivative (Esters/Acrylates - METHYL, ETHYL, BUTYL, 2-EH; Polymers - Elastomers, Superabsorbent Polymers, Water Treatment Polymers; Other Derivatives), by Applications & Region - Global Forecast to 2020

Next Post

Terahertz and Infrared Spectroscopy Market by Spectrum , by Technology , by Application - Global Forecasts to 2020

Related Posts

Market Moves

Gerresheimer raises revenue guidance for 2022 to double-digit growth after strong first quarter

8th April 2022
Regeneron, Intellia to develop CRISPR/Cas9-based treatments
Market Moves

Metagenomi Closes Oversubscribed $175M Series B Financing to Advance Therapeutic Pipeline and Expand Novel Gene Editing Platform

29th January 2022
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Indian Pharma Industry To Grow By 9-11% In FY22- ICRA

7th January 2022
Market Moves

IQVIA Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance

26th October 2021
My Personal Therapeutics and Pentavere receive EUREKA AI Therapeutics Funding to support the development of My Personal Therapeutics - digital therapeutics for Lung Cancer
Manufacturing

Consumer Health Apps and Digital Health Tools Proliferate, Improving Quality and Health Outcomes for Patients, Says New Report from IQVIA Institute

2nd August 2021
Charities Pay $6 Million to Settle Medicare Kickback Allegations in Pharma Probe
Market Moves

Biopharma Market to grow at 10.6% CAGR between 2020 and 2027

3rd December 2020
Next Post

Terahertz and Infrared Spectroscopy Market by Spectrum , by Technology , by Application - Global Forecasts to 2020

Latest News

Global Biopharmaceutical Bioseparation Market Eyeing $20bn
Manufacturing

Global Biopharmaceutical Bioseparation Market Eyeing $20bn

4th July 2022
FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters
Manufacturing

FDA Advises Adding Omicron BA.4, 5 To COVID-19 Boosters

4th July 2022
COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters
Manufacturing

COVID-19 Omicron-Specific Vaccines Could Be Used As Boosters

4th July 2022
Fasenra shows consistent safety and sustained efficacy in long-term Phase III BORA trial in severe eosinophilic asthma
Manufacturing

AstraZeneca Cites Early Lung Cancer Immunotherapy Success

4th July 2022
FDA Experts Recommend Changing COVID Jab Formulation In Fall
Manufacturing

FDA Experts Recommend Changing COVID Jab Formulation In Fall

30th June 2022
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack

System

  • Search
  • Sitemap
  • RSS Feed

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Health & Nutrition
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In